Prospecting into CGT companies?

Biopharma companies are making record investments in CGTs. These novel technologies are also changing the way life science companies develop treatments and organize their businesses.

If you offer contract research, contract manufacturing, or clinical research services to organizations embracing C&GT, our guide is designed to give you a head start prospecting into this explosive sector of the biopharma market.

Ready for your guide?

What's in our CGT Guide?

Our goal is to give you a head-start prospecting into biotech & pharma companies who are exploring CGTs.

As the industry-leading sales intelligence platform crafted specifically for companies who sell into biotech and pharma, Zymewire is uniquely positioned to uncover opportunities that you can act on today.

Here is what you can expect to find:

Five emerging Cell Therapy companies

Access companies who have raised capital and are looking for development partners

Five emerging Gene Therapy Companies

Access information like 2022 fundraising, team size, and IND enabling studies starting in 2022/23

Need for Speed: Look for deeper integration across the drug development lifecycle

CGT's are unique because they tend to target smaller patient pools, and are administered as a one-and-done treatment. As a result, whoever brings a drug to market first will capture a majority of the opportunity while rewards diminish rapidly for late entrants.

Much of what makes C&GT companies unique is driven by one factor: the critical need to move quickly. It has never been more important to identify early-stage opportunities.

Build vs Buy: CGTs are presenting new opportunities to partners across the value chain

Biopharma companies pursuing CGTs are reevaluating what parts of the drug development process they want to outsource, and what they want to keep in-house.

As a result, new partnership opportunities available across the value chain: from research and other preclinical activities to sourcing and manufacturing.